Dossier assessment
Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to major bleeding
No comparison with appropriate comparator therapy possible; therefore added benefit currently not proven
Additional information
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.
Project details
- Project no.
- A19-76
- Commission
- Commission awarded on 30.08.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76
Status: Commission completed
-
Dossier assessment
Andexanet alfa (acute major bleeding) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed